Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
and GENEVA, Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373).
- and GENEVA, Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373).
- This agreement brings the pending arbitration related to the APA to a close.
- "We look forward to a long-term partnership with Gavi to provide continued access to our protein-based non-mRNA COVID-19 vaccine."
- It is good for global immunisation, for countries and for healthy manufacturing markets," said David Marlow, Chief Executive Officer (ad int) of Gavi, the Vaccine Alliance.